Mohit Bansal
Stock Analyst at Wells Fargo
(4.28)
# 339
Out of 5,182 analysts
199
Total ratings
65.25%
Success rate
9.38%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Overweight | $135 → $150 | $120.84 | +24.13% | 14 | Mar 12, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $235 → $250 | $188.27 | +32.79% | 4 | Feb 25, 2026 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $65 → $75 | $65.40 | +14.68% | 8 | Feb 19, 2026 | |
| AMGN Amgen | Maintains: Equal-Weight | $325 → $375 | $353.28 | +6.15% | 13 | Feb 19, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $70 → $75 | $57.24 | +31.03% | 7 | Feb 18, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $180 → $175 | $132.56 | +32.02% | 8 | Feb 13, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $150 → $165 | $140.30 | +17.61% | 14 | Feb 11, 2026 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $200 | $183.78 | +8.83% | 16 | Feb 9, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $55 → $60 | $61.73 | -2.80% | 11 | Feb 6, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,200 → $1,280 | $954.52 | +34.10% | 19 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $745 → $800 | $777.25 | +2.93% | 22 | Feb 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $5 | $3.90 | +28.21% | 6 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $1.31 | +510.69% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $515 | $447.26 | +15.15% | 12 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $26.41 | +108.25% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $260 | $214.98 | +20.94% | 10 | Sep 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $35 | $31.42 | +11.39% | 5 | Sep 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $150 | $89.42 | +67.75% | 2 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $47 | $56.69 | -17.09% | 2 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $18.92 | +58.56% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $40.50 | +72.84% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $28.55 | +5.08% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $24.86 | +7,442.24% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $6.25 | +476.00% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $7.77 | +144.53% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.14 | +5,186.34% | 4 | Dec 3, 2019 |
Merck & Co.
Mar 12, 2026
Maintains: Overweight
Price Target: $135 → $150
Current: $120.84
Upside: +24.13%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $235 → $250
Current: $188.27
Upside: +32.79%
Halozyme Therapeutics
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $65 → $75
Current: $65.40
Upside: +14.68%
Amgen
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $325 → $375
Current: $353.28
Upside: +6.15%
BioMarin Pharmaceutical
Feb 18, 2026
Maintains: Overweight
Price Target: $70 → $75
Current: $57.24
Upside: +31.03%
Neurocrine Biosciences
Feb 13, 2026
Maintains: Overweight
Price Target: $180 → $175
Current: $132.56
Upside: +32.02%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $150 → $165
Current: $140.30
Upside: +17.61%
Biogen
Feb 9, 2026
Maintains: Equal-Weight
Price Target: $190 → $200
Current: $183.78
Upside: +8.83%
Bristol-Myers Squibb Company
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $55 → $60
Current: $61.73
Upside: -2.80%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,200 → $1,280
Current: $954.52
Upside: +34.10%
Feb 2, 2026
Maintains: Equal-Weight
Price Target: $745 → $800
Current: $777.25
Upside: +2.93%
Jan 5, 2026
Maintains: Equal-Weight
Price Target: $3 → $5
Current: $3.90
Upside: +28.21%
Dec 16, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $1.31
Upside: +510.69%
Dec 10, 2025
Maintains: Overweight
Price Target: $460 → $515
Current: $447.26
Upside: +15.15%
Nov 11, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $26.41
Upside: +108.25%
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $214.98
Upside: +20.94%
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $31.42
Upside: +11.39%
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $89.42
Upside: +67.75%
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $56.69
Upside: -17.09%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $18.92
Upside: +58.56%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $40.50
Upside: +72.84%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $28.55
Upside: +5.08%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $24.86
Upside: +7,442.24%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $6.25
Upside: +476.00%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $7.77
Upside: +144.53%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.14
Upside: +5,186.34%